References of "Foidart, Jacqueline"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEstimation de la fonction rénale chez le patient anorexique
Delanaye, Pierre ULg; Radermecker, Régis ULg; Saint-Remy, Annie ULg et al

in Diabètes & Métabolism (2004), 30

Detailed reference viewed: 87 (5 ULg)
Full Text
Peer Reviewed
See detailWhole-body tumor imaging using PET and 2-18F-fluoro-l-tyrosine: Preliminary evaluation and comparison with 18F-FDG
Hustinx, Roland ULg; Lemaire, Christian ULg; Jerusalem, Guy ULg et al

in Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine (2003), 44(4), 533-539

18F-FDG PET imaging is now established as a valuable tool for evaluating cancer patients. However, a limitation of 18F-FDG is its absence of specificity for tumor. Both protein synthesis and amino acid ... [more ▼]

18F-FDG PET imaging is now established as a valuable tool for evaluating cancer patients. However, a limitation of 18F-FDG is its absence of specificity for tumor. Both protein synthesis and amino acid transport are enhanced in most tumor cells, but their metabolism is less affected in inflammation. We therefore decided to evaluate the ability of PET with 2-18F-fluoro-L-tyrosine (18F-TYR) to visualize cancer lesions in patients compared with 18F-FDG PET. Methods: 18F-FDG PET and 18F-TYR PET were performed on 23 patients with histologically proven malignancies (11 non-small cell lung cancers (NSCLCs), 10 lymphomas, and 2 head and neck carcinomas). Fully corrected, whole-body PET studies were obtained on separate days. 18F-FDG studies were performed after routine clinical fashion. 18F-TYR studies were started 36 ± 6 min after tracer injection and a second scan centered over a reference lesion was acquired after completion of the whole-body survey-on average, 87 min after injection. Standardized uptake values (SUVs) were calculated for all abnormal foci and for various normal structures. Results were compared with pathologic or correlative studies. Results: 18F-FDG PET correctly identified 54 malignant lesions, among which 36 were also visualized with 18F-TYR (67%). 18F-TYR did not detect any additional lesion. Tumor SUVs (SUVbw, 5.2 vs. 2.5), tumor-to-muscle (7.4 vs. 2.7), and tumor-to-mediastinum activity ratios (3 vs. 1.4) were higher with 18F-FDG than with 18F-TYR. Two of 11 NSCLCs and 4 of 10 lymphomas were understaged with 18F-TYR compared with 18F-FDG. Although the NSCLC lesions missed by 18F-TYR PET were small, several large lymphoma lesions did not accumulate the tracer. In 4 patients, 18F-TYR-positive lesions coexisted with 18F-TYR-negative lesions. There was a high physiologic 18F-TYR uptake by the pancreas (average SUVbw, 10.3) and the liver (average SUVbw, 6.3). Muscle and bone marrow uptakes were also higher with 18F-TYR than with 18F-FDG: average SUVbw, 1 versus 0.7 and 2.6 versus 1.8, respectively. There was no change over time in the 18F-TYR uptake by the tumors or the normal structures. Conclusion: 18F-TYR PET is not superior to 18F-FDG PET for staging patients with NSCLC and lymphomas. [less ▲]

Detailed reference viewed: 94 (5 ULg)
Full Text
Peer Reviewed
See detailRadiothérapie métabolique des douleurs osseuses métastatiques
Hustinx, Roland ULg; Sautois, Brieuc ULg; Jerusalem, Guy ULg et al

in Médecine et Hygiène (2003), 61

La radiothérapie métabolique des métastases osseuses est un traitement palliatif de la douleur. Cet objectif est rempli dans la grande majorité des cas, sans effets secondaires cliniquement ressentis par ... [more ▼]

La radiothérapie métabolique des métastases osseuses est un traitement palliatif de la douleur. Cet objectif est rempli dans la grande majorité des cas, sans effets secondaires cliniquement ressentis par le patient. Tous les patients en dissémination osseuse ne peuvent cependant bénéficier de cette approche qui, lorsqu'elle est choisie, doit toujours être appliquée dans un cadre multidisciplinaire. Les lésions accessibles à ce traitement doivent avoir démontré leur caractère ostéocondensant en scintigraphie. La fonction rénale et la réserve médullaire sont des paramètres importants, l'élimination des radiopharmaceutiques étant urinaire et leur toxicité, médullaire. Les situations particulières telles que risque fracturaire important ou compression médullaire sont des contre-indications. Le traitement est simple dans son principe et dans sa réalisation. Il permet une amélioration très significative de la qualité de vie, tout en réalisant des économies substantielles en terme de coût de santé publique. [less ▲]

Detailed reference viewed: 74 (1 ULg)
Full Text
Peer Reviewed
See detailLes lymphomes
Jerusalem, Guy ULg; Hustinx, Roland ULg; Beguin, Yves ULg et al

in Médecine Nucléaire : Imagerie Fonctionnelle et Métabolique (2003), 27(8), 401-410

Actuellement, on arrive à guérir 70-80% des patients atteints de maladie de Hodgkin et 50% des patients atteints de lymphome non-Hodgkinien de malignité intermédiaire ou élevée. Une approche systématique ... [more ▼]

Actuellement, on arrive à guérir 70-80% des patients atteints de maladie de Hodgkin et 50% des patients atteints de lymphome non-Hodgkinien de malignité intermédiaire ou élevée. Une approche systématique concernant le diagnostic, la classification de la maladie et la détermination des facteurs pronostiques permet de choisir la thérapeutique la plus appropriée. Les auteurs passent en revue les examens à réaliser au diagnostic et discutent de la place de la tomographie à émission de positons (TEP) dans cette indication. Ils évoquent ensuite le problème des masses résiduelles. La TEP est maintenant l'examen de choix pour établir le bilan de fin de traitement. Les auteurs discutent également du rôle potentiel de la TEP pour l'évaluation thérapeutique précoce et le suivi régulier des patients après traitement pour lymphome. Enfin, l'aspect particulier des lymphomes de l'enfant est abordé. [less ▲]

Detailed reference viewed: 43 (12 ULg)
Full Text
Peer Reviewed
See detailComment etablir le bilan de fin de traitement des patients atteints de lymphomes non-hodgkiniens (LNH) de malignite intermediaire ou elevee?
Warland, V.; Jerusalem, Guy ULg; Hustinx, Roland ULg et al

in Revue Médicale de Liège (2002), 57(12), 779-84

Incomplete regression of a lymphomatous mass after chemotherapy and/or radiotherapy constitutes a major problem in the treatment of lymphoma. In patients with persisting tumor, it could be reasonable to ... [more ▼]

Incomplete regression of a lymphomatous mass after chemotherapy and/or radiotherapy constitutes a major problem in the treatment of lymphoma. In patients with persisting tumor, it could be reasonable to use salvage therapy and possibly hematopoietic stem cell transplantation at the time of minimal disease rather than at the time of clinically overt relapse. The authors reviewed the most appropriate imaging techniques for the assessment of response to treatment. The limitations of CT and MRI for predicting the nature of residual masses are well known. 67Ga scintigraphy has become a standard procedure for the posttreatment evaluation of patients with lymphoma, but it appears that 18F-FDG PET may be a more effective method. Personal experience in the field of PET scan is reported. Although PET should be considered the noninvasive imaging modality of choice, a histological confirmation of residual disease is always necessary before starting salvage therapy. 18F-fluorodeoxyglucose is not a tumor specific radiotracer. [less ▲]

Detailed reference viewed: 54 (0 ULg)
Full Text
Peer Reviewed
See detailTEP et tumeurs endocrines
Rigo, Pierre ULg; Belhocine, Tarik; Hustinx, Roland ULg et al

in Médecine Nucléaire : Imagerie Fonctionnelle et Métabolique (2000), 24(5), 275-282

Les auteurs passent en revue les indications de la TEP et en particulier du 18FDG dans l'évaluation des diverses tumeurs endocrines de la thyroïde, des parathyroïdes, des surrénales et de l'hyophyse. Les ... [more ▼]

Les auteurs passent en revue les indications de la TEP et en particulier du 18FDG dans l'évaluation des diverses tumeurs endocrines de la thyroïde, des parathyroïdes, des surrénales et de l'hyophyse. Les tumeurs neuroendocrines, gastroentéropancréatiques et carcinoïdes, sont également analysées. Habituellement, les tumeurs différenciées ayant une faible activité métabolique et proliférative, elles ne fixent que peu le FDG. Dans l'évaluation des tumeurs endocrines, la TEP au FDG n'intervient en général pas en première intention mais elle joue un rôle complémentaire d'autres scintigraphies spécifiques. [less ▲]

Detailed reference viewed: 32 (3 ULg)
Peer Reviewed
See detailLe diabete gestationnel: definition, depistage et traitement.
Geronooz, I.; Scheen, André ULg; Foidart, Jacqueline ULg

in Revue Médicale de Liège (1999), 54(5), 429-33

Defined as glucose intolerance with onset or first recognition during pregnancy, gestational diabetes mellitus represents in fact an heterogeneous clinical entity which may concern 1 to 4% of all pregnant ... [more ▼]

Defined as glucose intolerance with onset or first recognition during pregnancy, gestational diabetes mellitus represents in fact an heterogeneous clinical entity which may concern 1 to 4% of all pregnant women in our country. Its adverse effects on the mother and her child, the need for a universal screening and the mode of screening are still controversial. Screening may be made either by a first test with a 50 g oral glucose load (the so-called O'Sullivan test), confirmed if positive by a 100 g oral glucose tolerance test (OGTT), or at first glance by a 75 g OGTT performed between the 24th and 28th weeks of gestation. The treatment of gestational diabetes is based on diet. In case of diet failure to obtain good glucose control, insulin therapy should be proposed. [less ▲]

Detailed reference viewed: 180 (3 ULg)
Full Text
See detailUn syndrome de Cushing d'origine inexpliquée
Geenen, Vincent ULg; Foidart, Jacqueline ULg; Krzesinski, Jean-Marie ULg

in Actualité Médicale Belge (1996), 513

Un homme de 25 ans est hospitalisé en août 1994 au CHU de Liége en vue de l'exploration de lombolgies chroniques et de manifestations cliniques d'hypercorticisme. Il présente en effet un visage boursouflé ... [more ▼]

Un homme de 25 ans est hospitalisé en août 1994 au CHU de Liége en vue de l'exploration de lombolgies chroniques et de manifestations cliniques d'hypercorticisme. Il présente en effet un visage boursouflé avec une érythrase discrète et une augmentation de poids (prise de 10 kg en quelques mois) à localisation tronculaire prédominante. Ces symptômes s'accompagnent d'une asthénie importante et de crampes musculaires au niveau des extrémités. [less ▲]

Detailed reference viewed: 22 (3 ULg)
Peer Reviewed
See detailLocalisation scintigraphique de tumeurs neuroendocrines et de leurs métastases par un analogue de la somatostatine: [111In-DTPA-d-phe1] octréotide.
Beckers, Albert ULg; Pham, V. T.; Abs, R. et al

in Revue Médicale de Liège (1993), 48(6), 326-34

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailIn-vivo studies on Haemaccel-fibronectin interaction in man.
Damas, Pierre ULg; Adam, Aurore ULg; Buret, J. et al

in European Journal of Clinical Investigation (1987), 17(2), 166-73

An enzyme-linked immunoassay has been recently set up for direct measurement of the binding capacity of plasma fibronectin to gelatin. This binding capacity could be completely inhibited in vitro by an ... [more ▼]

An enzyme-linked immunoassay has been recently set up for direct measurement of the binding capacity of plasma fibronectin to gelatin. This binding capacity could be completely inhibited in vitro by an eight-fold excess of gelatin, of Haemaccel, but not of Geloplasma. On the contrary, the levels of immunoreactive fibronectin measured by laser nephelometry did not change, in presence of 10 to 1000 micrograms ml-1 of gelatin, of Haemaccel or of Geloplasma. When infused into normal volunteers, Haemaccel provoked a strong and immediate inhibition of the plasma fibronectin binding capacity to gelatin. This inhibition was dose-dependent and maximal after infusion of 500 ml of Haemaccel. Twenty-four hours after this infusion, there was a progressive recovery of the gelatin-binding capacity, which was almost completely achieved 96 h later. The formation of complexes between Haemaccel and fibronectin was demonstrated by gel filtration chromatography and by affinity chromatography. Immunoreactive plasma fibronectin levels remained unchanged up to 24 h after infusion of 500 ml of Haemaccel. A transient decline to 50% of its initial value then occurred the second day after the infusion. Therefore, a delay existed between the formation of fibronectin-Haemaccel complexes and their elimination from the bloodstream. This delay decreased when smaller volumes of Haemaccel were infused, which strongly suggests that plasma fibronectin is cleared by means of Haemaccel and does not seem to play a role of opsonin in these conditions.(ABSTRACT TRUNCATED AT 250 WORDS) [less ▲]

Detailed reference viewed: 49 (9 ULg)